SCHEDULE: Capital World Investors Discloses 5.7% Stake in NovoCure

Capital World Investors has disclosed a 5.7% passive ownership stake in NovoCure Ltd., holding over 6.38 million common shares.

Summary

• Capital World Investors (CWI) reported beneficial ownership of 6,382,848 common shares of NovoCure Ltd.
• This stake represents 5.7% of NovoCure's outstanding common stock, based on 111,485,634 shares believed to be outstanding.
• The filing is a Schedule 13G, indicating a passive investment intent by Capital World Investors.
• The event requiring this filing, where CWI crossed the 5% beneficial ownership threshold, occurred on June 30, 2025.
• CWI, a division of Capital Research and Management Company, holds sole voting and dispositive power over all reported shares.

Sentiment

Score: 7

Explanation: A significant passive stake by a major institutional investor is generally a positive signal of confidence, though it doesn't provide operational or financial performance details.

Positives

• A prominent institutional investor, Capital World Investors, has taken a significant 5.7% stake in NovoCure Ltd., potentially signaling confidence in the company's long-term prospects.
• The investment is classified as passive, indicating CWI's intent not to seek control or influence management, which can be viewed positively by current management and other shareholders.

Negatives

• No specific negative information is disclosed in this Schedule 13G filing.

Risks

• The filing itself does not detail specific company risks, as it is a disclosure of beneficial ownership.
• Investment in NovoCure Ltd. common stock carries inherent market risks, including potential fluctuations in share price.

Future Outlook

This Schedule 13G filing does not provide forward-looking statements or guidance regarding NovoCure Ltd.'s future outlook.

Management Comments

• This filing does not contain direct quotes or paraphrased statements from NovoCure Ltd.'s management.

Industry Context

This filing primarily concerns an institutional ownership disclosure and does not provide specific insights into broader industry trends or competitive landscape for NovoCure Ltd.

Comparison to Industry Standards

• This filing is a disclosure of beneficial ownership and does not contain information for direct comparison to industry-specific operational or financial benchmarks.

Stakeholder Impact

• Shareholders: May view the institutional investment as a positive signal, potentially increasing confidence in the stock.
• Management: The passive nature of the investment suggests no immediate challenge to control, allowing management to focus on operations.

Next Steps

• Capital World Investors will file amendments to this Schedule 13G if their beneficial ownership percentage changes by more than 1% or if their investment intent changes from passive.

Key Dates

Recommendation

The filing indicates a significant passive investment by a reputable institutional investor, Capital World Investors, in NovoCure Ltd. While this signals a vote of confidence, the Schedule 13G itself does not provide operational or financial performance data to warrant a 'buy' or 'sell' recommendation. It primarily confirms a substantial institutional holding, which can be a positive long-term indicator, thus supporting a 'hold' position for investors awaiting further fundamental updates.

Keywords

NovoCure, NVCR, Capital World Investors, CWI, Institutional Ownership, SEC Filing, Schedule 13G, Common Stock, Investment, Healthcare